Skip to main content

Matsuda Masaru's Form 4 filing

Arcutis Biotherapeutics, Inc. (ARQT) · filed Mar 3, 2026

Accession no.
0001628280-26-014326
Filed
Mar 3, 2026
Trade date
Feb 27-Mar 2, 2026
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $313.9K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Matsuda MasaruCIK 0001798679Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 27, 2026Common StockAGrant or awardAcquired+37,000$0.00$0147,003Direct
Feb 27, 2026Common StockSSaleDisposed−3,325$27.95−$92,933.75143,678Direct
Mar 2, 2026Common StockSSaleDisposed−6,553$25.16−$164,873.48137,125Direct
Mar 2, 2026Common StockSSaleDisposed−193$25.91−$5,000.63136,932Direct
Mar 2, 2026Common StockSSaleDisposed−1,987$25.70−$51,065.9136,932Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 27, 2026Common StockAGrant or awardAcquired+97,000$0.00$097,000Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)